Podcasts about ii iii

Far-right Russian thinker Aleksandr Dugin just sat down with Glenn Greenwald for an extensive interview, and we can't look away. Deep State Kuba joins Ben Burgis to watch some of it and discuss. Before that, Ben does an Opening Argument on the issues raised by the outrageous assault on free speech at Columbia. At the end of the main show, we play some of Daniel Tutt's guest appearance on Ben Burgis's Sunday afternoon Zoom Capital class to talk about the lumpenproletariat and tease Richard Wolff's guest lecture next Sunday. (Anyone who wants can join the class at patreon.com/benburgis and get instant access to all 25 class recordings so far, and of course join live for the approximately one trillion Sundays we've got left in the class (eight more chapters left in Vol. I, plus the entirety of Vols. II + III). Last but very far from least, in the postgame for patrons Ben and the crew chat with Yuri Rashkin, who actually did a Russian-language debate with Dugin a couple of years ago. Ben is accused of spreading "Kremlin propaganda" but somehow everyone parts as friends.Buy tickets for Ben's live show with Jason Myles on April 17th in San Francisco:https://www.universe.com/events/is-trump-the-end-of-history-tickets-J30WT9Follow Kuba on Twitter: @DrKuba2Follow Daniel on Twitter: @DanielTuttFollow Ben on Twitter: @BenBurgisFollow GTAA on Twitter: @Gtaa_ShowBecome a GTAA Patron and receive numerous benefits ranging from patron-exclusive postgames every Monday night to our undying love and gratitude for helping us keep this thing going:patreon.com/benburgisRead the weekly philosophy Substack:benburgis.substack.com

Join us this week for our massive breakdown of all the latest Bungie livestream info, going over the new activity; Court of Blades and the rest of the Act 2 & 3 details for Episode Heresy. We detail all the latest changes with the upcoming Guardian Games event coming this Tuesday at reset, including the new boss-rush mode Rushdown. We chat about the welcome improvements to the Trials of Osiris and Comp game modes. Respawn gets all emotional about the Sundered Doctrine Dungeon weapons and Monster Hunter for the 5 minutes we let him. Plus we have a few tips and tricks to help.   00:00:00 – Opening & Monster Hunter Chat 00:03:56 - More Monster Hunter Ramblings 00:04:49 - Introductions 00:06:03 - Moments of Triumph 2024 00:08:10 - Vault Space 00:17:51 - Trials of Osiris & Redrix's Estoc 00:31:08 - 14th Dregen Title Reset & Sundered Shenanigans 00:43:48 - Barrow-Dyad & Other Exotic Submachine Guns 00:50:24 - Moments Again 00:52:54 - Exo Body, Yes Please 00:54:03 - Heresy Act 2 Livestream Breakdown 01:01:02 - Dungeon Weapon Diversion 01:08:12 - Heresy Act 2 Weapon Breakdown 01:29:38 - Artifact Update & This Week at Bungie: March 6th 2025 01:29:38 - Heresy Act 3 Preview 01:40:53 - Rite Of The Nine Information 01:44:45 - Rite Of The Nine Weapons 01:52:57 - Guardian Games 2025 Information 01:55:25 - Guardian Games Weighting Issues In The Past 01:59:17 - Rushdown - New Boss Rush Mode 02:00:58 - Guardian Games Weapons 02:01:58 - Guardian Games Warning 02:03:17 - Guardian Games Glows 02:08:12 - Guardian Games Eververse 02:10:24 - Guardian Games Skimmer 02:12:05 - Guardian Games Cards & Rewards 02:15:09 - Guardian Games Rushdown Roulette 02:18:33 - Heresy Act 2 Crucible Update 02:28:06 - Trials This Week & Account Update 02:31:15 - Bungie Store Sale 02:32:30 - More Fashion Feedback 02:33:21 - Daylight Savings 02:34:18 - Account Recovery & Cheating 02:35:55 - Peroty's Player Support 02:43:34 - End Of The TWAB 02:44:38 - This Week In Destiny: Heresy Act 2 - Week 6 02:55:56 - Respawn Report Round-Up 02:59:49 - Tips, Tricks & Guides & Builds 03:08:16 - Patreon Thanks & End of the Show 03:11:47 - End Two Titans and a Hunter YouTube Channel Two Titans and a Hunter Twitch Two Titans and a Hunter Discord Two Titans and a Hunter - Patreon Two Titans and a Hunter Ko-Fi The100 io – GH/GD/2TAAH Group Email: twotitansandahunter@hotmail.com Two Titans and a Hunter Twitter Two Titans and a Hunter – Facebook Artwork by @Nitedemon Xbox Live: Nitedemon, Peroty, Not Arf & No1RespawnsInRL End credits theme song by Elsewhere - YouTube Channel Plus as always, thank you to Alexander at Orange Free Sounds & www.freesound.org for all the sound effects used in our podcast.  Required Stuff: Bungie - This Week at Bungie March 6th 2025 360GameTV - Old Season Pass Access Daltnix - 0.43 TTK Hunter PvP Build Spade - The Most Terrifying Prismatic PvP Hunter Build Aztecross - Unkillable Titan PvE Build Esoterickk - Solo GM Titan Sword Build Duddits II - Crazy Kinetic Tremors/Elemental Honing Mactics - Best Meta Titan PvE Build Jackeddidge - 27 Free Raid Chest For Solo's Maven - It's Better Than You Think: Titan Build Esoterickk - YouTube Channel Twitch - GuardianDownBot Raid Checkpoints Twitch - IceBreakerCatty. Pluderthabooty Channel Mactics Channel Engram.Blue Link

www.fed965.comCollaborations, Meetings, Sessions — babyblueviperbusiness@gmail.com .X — Chill0006YouTube — Baby Blue ViperLinkedIn — Federico Blanco Sánchez-Llanos This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.fed965.com/subscribe

El Dr. Saúl Campos Gómez, oncólogo médico del Centro Oncológico Estatal, ISSEMYM en Toluca, Estado de México, nos habla durante el 7º Taller RISE 2025: Residents In Search of Excellence del Colegio Mexicano de Oncología Médica, sobre CPCNP EC II-III: enfermedad resecable tratamiento adyuvante.Gracias al apoyo educativo de Johnson & Johnson México.La realización integral de este evento fue gracias a: AstraZeneca México y Pfizer México. Fecha de grabación: 31 de enero de 2025.        Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

El Dr. Francisco Zambrana Tévar, oncólogo médico del Hospital Universitario Infanta Sofía, San Sebastián de los Reyes en Madrid, España presentó un análisis de los estudios más relevantes del año 2024 en cáncer de próstata.STAMPEDE: estudio fase II/III, controlado aleatorizado de múltiples brazos y múltiples etapas. Su objetivo es evaluar múltiples estrategias terapéuticas en el tratamiento del cáncer de próstata metastásico localmente avanzado y de alto riesgo sin tratamiento hormonal.DIPPER: estudio fase II, abierto, multicéntrico y aleatorizado  de radioterapia de rescate temprana versus vigilancia para la recurrencia bioquímica después de una prostatectomía radical que incorpora estratificación del riesgo basada en la clínica y en imágenes.EMBARK: estudio fase III, aleatorizado que evalúa la eficacia y seguridad de enzalutamida más leuprolida, enzalutamida en monoterapia y placebo más leuprolida en pacientes con cáncer de próstata no metastásico de alto riesgo que progresaron después de una terapia definitiva.HORRAD: estudio fase III, aleatorizado, que evaluó el impacto de la radioterapia dirigida al tumor primario en pacientes con cáncer de próstata metastásico al momento del diagnóstico.PEACE-1: estudio fase III, prospectivo y aleatorizado que evalúa la terapia de deprivación androgénica sola o en combinación con docetaxel, radioterapia local y/o acetato de abiraterona con prednisona en pacientes con cáncer de próstata metastásico aún sensible a la castración.CHAARTED: estudio aleatorizado de terapia de ablación androgénica con o sin quimioterapia en el tratamiento de pacientes con cáncer de próstata metastásico.CARD: esudio fase III, aleatorizado que evaluó la eficacia de cabazitaxel en comparación con la reintroducción de abiraterona o enzalutamida en pacientes con cáncer de próstata metastásico resistente a la castración que ya habían recibido previamente docetaxel y una línea de terapia hormonal de nueva generación (abiraterona o enzalutamida).TheraP: estudio fase II, aleatorizado y de etiqueta abierta que comparó Lu177-PSMA-617 vs. cabazitaxel en pacientes con cáncer de próstata metastásico resistente a la castración previamente tratados con docetaxel.IMPACT: ensayo clínico fase III que evaluó la eficacia de sipuleucel-T en pacientes con cáncer de próstata metastásico resistente a la castración asintomático o mínimamente sintomático.Entre otros...  Fecha de grabación: noviembre de 2024.                     Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

El Dr. Ricardo Brugés, oncólogo médico del Instituto Nacional de Cancerología en Bogotá, Colombia, presentó un análisis de los estudios más relevantes del año 2024 en cáncer de cabeza y cuello. Estudio clínico que evaluó el bloqueo adyuvante de PD-1 con camrelizumab en pacientes con carcinoma nasofaríngeo localmente avanzado de alto riesgo. Ensayo clínico en población asiática, aleatorizado y controlado fase III de endostar combinado con quimiorradioterapia concurrente frente a quimiorradioterapia concurrente sola para el carcinoma nasofaríngeo localmente avanzado Epstein-Barr positivo. Resultados actualizados del estudio con inmunoterapia basada en arenavirus más pembrolizumab como tratamiento en pacientes con cáncer de cabeza y cuello recurrente/metastásico positivo para VPH16. JCOG1008: Análisis final del ensayo fase II/III de quimiorradioterapia postoperatoria comparando cisplatino cada 3 semanas con cisplatino semanal en pacientes de alto riesgo con carcinoma de células escamosas de cabeza y cuello. LBA36: Estudio aleatorizado fase II para evaluar la eficacia y seguridad de la terapia deprivación androgénica frente a quimioterapia en pacientes con cánceres de glándulas salivales recurrentes y/o metastásicos que expresan el receptor de andrógenos. MYTHOS: Resultados del estudio fase II de trastuzumab deruxtecan en pacientes con cáncer de glándulas salivales recurrente/metastásico HER2-positivo. Validación del ADN tumoral circulante asociado al virus del papiloma humano (VPH) para la detección de enfermedad mínima residual y predicción de recurrencia en pacientes con cáncer de cabeza y cuello asociado a VPH tratados con cirugía. Fecha de grabación: 3 de noviembre de 2024.                     Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

Back to the Future Part II & III is a platform game based on the movies of the same name. The object of the game is to collect misplaced objects from various time periods like 1955, 1985 and 2015, and bring them back to their proper time period and location. The game often requires the player to solve a small puzzle to figure out what item fits the location he has found. Support NEStalgia directly by becoming a member of our Patreon at https://www.patreon.com/Nestalgia Members at the $5 and above level get access to our brand new show NEStalgia Bytes. A look at the famicom games you can play without any Japanese knowledge! For More NEStalgia, visit www.NEStalgiacast.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

El Dr. Javier Martín Broto, oncólogo médico del Hospital Universitario Fundación Jiménez Díaz en Madrid, España, presenta un resumen de los estudios que considera más relevantes en el ámbito de sarcomas expuestos durante el Congreso de ESMO 2024. EREMIS: estudio fase II que evaluó el uso de regorafenib como terapia de mantenimiento en sarcomas de partes blandas. Este diseño incluyó pacientes que recibieron previamente seis ciclos de quimioterapia basada en doxorrubicina y lograron al menos una estabilización o una respuesta objetiva. GEIS-52: estudio fase II, el cual es parte de una investigación impulsada por el grupo español de investigación en sarcomas que explora la combinación de sunitinib y nivolumab en pacientes con sarcoma de tejidos blandos. C-800-01: estudio fase I que evaluó botensilimab más balstilimab en una de las cohortes de angiosarcomas y sarcomas. Multisarc: estudio fase II/III, aleatorizado de medicina de precisión en sarcomas avanzados de tejidos blandos para la identificación de alteraciones genéticas accionables. Estudio que evalúa lenvatinib frente a placebo en pacientes con tumores del estroma gastrointestinal en progresión, específicamente en aquellos que han progresado después de recibir al menos tratamientos previos con imatinib y sunitinib. Estudio que analiza olverembatinib en tumores del estroma gastrointestinal de tipo wall type con deficiencia de SDH. En este estudio olverembatinib muestra una actividad superior a la observada con regorafenib y sunitinib en términos de supervivencia libre de progresión. AXAGIST: estudio fase II que evalúa la combinación de avelumab (un inhibidor de PD-L1) y axitinib (un inhibidor de VEGFR) en pacientes con tumores del estroma gastrointestinal avanzados o metastásicos que han progresado después de terapias estándar. 1721MO: estudio que evalua la seguridad y eficacia de olutasidenib, un inhibidor de la mutación IDH1, para el tratamiento del condrosarcoma con mutación IDH1 recurrente/recidivante o localmente avanzado o metastásico. MOTION: estudio fase III, aleatorizado, controlado con placebo y doble ciego de vimseltinib (DCC-3014) para el tratamiento del tumor de células gigantes tenosinoviales.     Fecha de grabación: 10 de octubre de 2024.                            Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

El UCAM Murcia ha vivido su mejor semana de lo que llevamos de curso en cuanto a sensaciones de juego y resultados ya que venció al Casademont Zaragoza (88-74) y también al FMP serbio en BCL (86-50). Sin embargo, ese partido dejó la lesión de Troy Caupain. El base americano tiene un esguince de grado II-III, que podría tenerle alejado de las pistas entre mes y medio y dos meses. Es poco probable que le veamos jugar antes del parón por las Ventanas FIBA, para el que quedan 4 partidos de Liga Endesa. Repasamos la actualidad del equipo en la tertulia con Andrés Miso, Laura Fernández y Emilio Sánchez-Bolea. También la de la Liga Endesa con el periodista Chema de Lucas.El Hozono Global Jairis está firmando un arranque de curso espectacular. El domingo pasado compitió a un nivel altísimo en la pista de uno de los mejores equipos de Liga Femenina Endesa y que también juega en Euroliga como es el Casademont Zaragoza. Sólo una canasta sobre la bocina de Atkinson hizo que las murcianas se quedasen sin la victoria (70-68). Decía Bernat Canut que quería ver cómo jugaba su equipo después de derrota y tiene que estar encantado porque el Jairis venció en la pista del Angers ayer en Eurocup, equipo invicto en la competición europea y en la liga francesa (66-80). Este domingo recibirán en el Fausto Vicent la visita del Baxi Ferrol.En Primera FEB, el Odilo FC Cartagena cayó en su visita a Zamora (94-83). Este sábado recibirán en el Palacio de los Deportes al Hestia Menorca (19h). Con victoria cerró la jornada La Salud de Archena, en Segunda FEB, en la pista del Zornotza (62-71). El sábado jugarán en casa ante el Ciudad de Huelva (19h).

  A me le retrospettive sono sempre piaciute, alla fine ho deciso di farne una anche io con l’aiuto di Lorenzo e di Carmelo. Dopo un pò di tempo ho deciso che era giunta l’ora di occuparsi di tutti i giochi della serie Ultima, spinoff inclusi. Quest’anno secondo i miei calcoli saranno 13 anni che […]

"The doll's trying to kill me and the toaster's been laughin' at me!" Part 6 of our Simpsons deep dive. We watched: S02E03 - Treehouse of Horror S03E06 - Treehouse of Horror II S04E05 - Treehouse of Horror III

Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen to the boys' best bits from Barcelona on Day 2 of ESMO.Studies discussed in this episode:Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II studyA multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trialPathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based studyInterim analysis of GALAXIES Lung-201: belrestotug + dostarlimab in 1L for PD-L1 TPS >/= 50% NSCLCIvonescimab +/- ligufalimab + FOLFOXIRI as 1L treatment for mCRCEfficacy and safety of ribociclib + NSAI in younger patients with HR+/HER2- EBC (NATALEE)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comSpotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/nectaOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

ADA Compliance Directory now offers free ADA website audits and monthly monitoring and updates. These services can be used by local state governments (ADA Level II) and public businesses (ADA Level III). Learn more at https://www.ada-compliance.com US Enterprises LLC dba ADA Website Compliance City: Marlton Address: 525 Rte 73 N Website: https://www.ada-compliance.ai Phone: +1-856-856-3702 Email: brian@ada-compliance.ai

În 1968 Partidul Comunist Român, sub conducerea lui Nicolae Ceaușescu, a pornit un fals proces împotriva unor abuzuri ale Securității, din perioada în care PCR era condus de Gheorghe Gheorghiu-Dej iar ministru de interne și conducător de facto al Securității era Alexandru Drăghici. De fapt, Ceaușescu a vrut doar să își elimine concurența la conducerea partidului și să își creeze o imagine de reformator politic. În urma acestui proces a apărut falsa distincție între “securitatea rea”, stalinistă (dejistă) și “securitatea bună”, reformată după preluarea puterii în partid de către Nicolae Ceaușescu.Dar Securitatea nu a fost niciodată bună. Abuzurile și teroarea au continuat până în 1989.

Aralık Mag. Podcast serimizin 5. sezonu; Alman dilinin 20. yüzyıldaki en önemli yaratıcılarından olan Rainer Maria Rilke'nin, "Duino Ağıtları" isimli kitabında yer alan I. II. ve III. Ağıt bölümleri ile devam ediyor. Podcast bölümlerimizi tüm podcast platformlarından dinleyebilirsiniz. Yazan: Rainer Maria Rilke Çevirmen: Can Alkor Seslendiren: İlker Şimşekcan Dinlediğiniz için teşekkürler www.aralikmag.com #rainermariarilke #duinoağıtları #ilkersimsekcan #canalkor #aralikmag

paypal.me/LibroTobias Esta semana en nuestra “Sección principal” hago otro especial de series, por si es el último. Os hablo del tercer spin off de The Walking Dead, The Ones Who Live, os hablaré de las seis temporada de House of Cards, las dos temporadas de la serie Wolf Creek que surgió tras el éxito de las dos películas australianas con el mismo título y finalmente, años después de hablar de la primera temporada de True Detective os comento ahora las otras 3 temporadas. Además en nuestra sección “El callejón oscuro” os traigo a John Joseph Joubert IV, un asesino en serie declarado culpable de asesinar a tres niños, uno en Maine y dos en Nebraska y que acechaba a sus víctimas en un coche con el que rondaba por donde residían sus futura víctimas. A causa de la incompetencia de las autoridades locales y a que asesinó en dos estados diferentes, el FBI entro de lleno en su caso. Tiempos: Sección principal: del 00:03:51 al 03:26:33 Sección “El callejón oscuro”: del 03:26:34 al 04:23:52 Presentación, dirección, edición y montaje: Asier Menéndez Marín Diseño logo Podcast: albacanodesigns (Alba Cano) Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

On this week's episode of our show, Captain Ingle and I and our special guest Justin Toner set a course for the 24th AND 32nd centuries and the voyages of both the Enterprise-D and the Discovery. The reason for this is that in addition to the classic two-parter episode "Unification" from The Next Generation, the story was given a sequel of sorts in the form of the Discovery episode "Unification III", wherein the story of the Romulans and Vulcans continues. Join us as we go boldly! --- Send in a voice message: https://podcasters.spotify.com/pod/show/pageturnerstheywerenot/message

Want access to more wisdom in time? Get access to over 1,500 +1's (just like this!) and 650+ Philosopher's Notes (distilling life-changing big ideas from the best self-development books ever written) and a LOT more with our Heroic Premium membership. Learn more and get 30 days free at https://heroic.us

Playlist: La Yegros - BailarinToots & The Maytals - Funky KingstonDon Letts - The DoormanDubmatix - Pressure DubAna Tijoux - OyemeOkan - Eshu Nigue (Elegue)Afro-Peruvian New Trends Orchestra - Latino BluesSant Anna Bay Coconuts - No Pizza On My PineappleThe Surfers - HonoluluTerreur Twist - jabba jabba heyErin Ross - Stoke That FireHangman - Weatherman LiedOhama - Part In Peace (2024)Various, featuring African Revival - Soul MakossaSaigon Soul Revival - Ai Th​ậ​t L​ò​ng Y​ê​u AiShoukichi Kina, featuring Ry Cooder - Eternally EcstasyVarious Artists, featuring Toshiyuki Honda - Living in a CityJustin Saladino Band, featuring Ariel Posen - Fan The Flames (Live)Dave Alvin, Jimmie Dale Gilmore, The Guilty Ones - We're Still hereTreat Her Right - JunkyardYummi Wisler Guitar Combo - Albanian ShuffleOrkestar Kriminal - TO AMPELOPO​Ú​LI TOUShazalakazoo - ToulaOsmanthus - Variegated Forms I, II & III

Francis's favorite nephews continue down the literary journey by reading some more of Mario Puzo's Godfather source material; books 2, 3 and 4 of the eponymous novel. Find out just what Johnny Fontaine was up to after Jack Woltz found a horse head in his bedsheets as well as life with Sonny as the Don.

BUFFALO, NY- March 27, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, and Jennifer K. Litton from the University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, and Harvard Medical School conducted a clinical trial to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). “This feasibility study was conducted to begin testing the hypothesis that dual checkpoint blockade would increase TIL and enhance the response to subsequent NACT in patients with stage II or III HR+/HER2-negative breast cancer.” Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease. At the time of breast surgery, 1/8 patients had a pathologic complete response (pCR). The trial was stopped early after 3 of 8 patients experienced immunotherapy-related toxicity or suspected disease progression that prompted discontinuation or a delay in the administration of NACT. Two patients experienced grade 3 immune-related adverse events (1 with colitis, 1 with endocrinopathy). Analysis of the tumor microenvironment after combination immunotherapy did not show a significant change in immune cell subsets from baseline. “There was limited benefit for dual checkpoint blockade administered prior to NACT in our study of 8 patients with HR+/HER2-negative breast cancer.” DOI - https://doi.org/10.18632/oncotarget.28567 Correspondence to - Haven R. Garber - hrgarber@mdanderson.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28567 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, breast cancer, ER positive, immunotherapy, neoadjuvant chemotherapy, tumor microenvironment About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Visit learnAMAstyle.com for free downloads regarding editing and the AMA Manual of Style tip sheet.  Nexletol and Nexlizet for LDL Lowering and CV Risk: The FDA approved bempedoic acid (Nexletol) and its combination with ezetimibe (Nexlizet) for reducing cardiovascular risk and treating primary hyperlipidemia. Bempedoic acid inhibits a cholesterol synthesis enzyme, while ezetimibe blocks cholesterol absorption, both lowering LDL-C levels. The approval, for high-risk patients not yet having cardiovascular events, was based on the CLEAR Outcomes trial. Iclusig for ALL: The FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for treating previously untreated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib, a tyrosine kinase inhibitor, is the first targeted agent for this leukemia type in combination with chemotherapy, based on the PhALLCON trial results. Further confirmatory data may be required to verify its clinical benefit. Elahere for Ovarian Cancer: Mirvetuximab soravtansine-gynx (Elahere) received FDA approval for treating folate receptor alpha-positive, platinum-resistant ovarian cancer, marking it as the first antibody-drug conjugate in the U.S. for this condition. The treatment targets cancer cells by binding to the folate receptor alpha, delivering a cytotoxic agent. Approval was based on the Phase 3 MIRASOL trial. Duvyzat for DMD: The FDA approved givinostat (Duvyzat) for patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare neuromuscular condition. Givinostat is an HDAC inhibitor that mitigates muscle damage and slows disease progression. Approval was based on the EPIDYS trial results, granted to Italfarmaco S.p.A. Spevigo for Psoriasis: Spesolimab-sbzo (Spevigo) received FDA approval for treating generalized pustular psoriasis (GPP) in adults and pediatric patients, expanding its indication from initial approval for GPP flares. As the first targeted therapy for GPP, it acts as an IL-36 receptor antagonist. The expanded approval was based on the Effisayil 2 trial, showing significant reduction in GPP flares. Tryvio for Hypertension: The FDA approved aprocitentan (Tryvio) in combination with other antihypertensive drugs for adults not adequately controlled on other medications, marking it as the first new oral antihypertensive therapy pathway in nearly 40 years. Based on the PRECISION trial, aprocitentan was shown to be effective in patients with resistant hypertension. Opsynvi for PAH: Macitentan and tadalafil (Opsynvi) was approved by the FDA for adults with pulmonary arterial hypertension (PAH) and WHO functional class II-III, as the first once-daily single-tablet combination therapy for PAH. The approval was based on the A DUE study, demonstrating greater reduction in pulmonary vascular resistance compared to monotherapies. Lenmeldy for Juvenile Metachromatic Leukodystrophy: The FDA approved Lenmeldy (atidarsagene autotemcel) gene therapy for children with metachromatic leukodystrophy (MLD), a rare genetic disease affecting the brain and nervous system. The therapy uses the patient's own genetically modified stem cells to produce the missing enzyme. Approval was based on significant improvements in survival, mobility, and cognitive functions observed in clinical trials and an expanded access program.

After the 2024 Gastrointestinal Cancers Symposium, Jun Gong, MD, and Daneng Li, MD, sat down to discuss the most relevant trial data to have come from the conference. They convened for a live X Space hosted by CancerNetwork®. During the discussion, they covered different trials across the gastrointestinal space, which included those evaluating different disease states from hepatocellular carcinoma (HCC) to colorectal cancer (CRC), and those assessing circulating tumor DNA (ctDNA) dynamics. Gong, a hematologic oncologist focusing on gastrointestinal and genitourinary cancers at Cedars-Sinai Medical Center, and Li, an associate professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, each gave their perspective on the clinical trial data and discussed if they had implemented any of these study treatments into clinical practice.  The studies they covered included:  1.        Phase 3 NETTER-2 Trial (NCT03972488)1: - Investigated lutetium Lu 177 dotatate (Lutathera) plus octreotide vs octreotide alone for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). - Lutetium Lu 177 significantly improved progression-free survival (PFS) and overall response rate (ORR) compared with octreotide alone. - The agent may be considered for patients with high-grade GEP-NETs who desire significant tumor shrinkage. 2.        Phase 3 EMERALD-1 Trial (NCT03778957)2: - Studied transarterial chemoembolization (TACE) plus durvalumab (Imfinzi) with or without bevacizumab (Avastin) for unresectable HCC. - Durvalumab/bevacizumab plus TACE improved PFS compared with placebo plus TACE. - TACE may be preferred over transarterial radioembolization (TARE) due to faster patient recovery. 3.        Phase 3 CheckMate-8HW Trial3: - Evaluated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy for first-line treatment of microsatellite instability-high/mismatch repair deficient metastatic CRC. - Nivolumab/ipilimumab demonstrated superior PFS compared with chemotherapy. - Chemotherapy may no longer be the standard first-line treatment for this patient population. 4.        BESPOKE Study (NCT04264702)4: - Assessed the impact of minimal residual disease (MRD) detected by ctDNA on disease recurrence in patients with stage II and III CRC receiving adjuvant chemotherapy. - MRD positivity was associated with worse disease-free survival (DFS). - ctDNA clearance at 12 weeks indicated improved DFS.  5.        GALAXY Trial5: - ctDNA is a promising biomarker that can be used to predict recurrence in patients with CRC. - Patients with ctDNA-positive disease had a worse DFS than patients with ctDNA-negative disease. - This suggests that ctDNA may be useful for making treatment decisions, but more research is needed before it can be used in clinical practice. 6.        Phase 3 FRESCO-2 Trial (NCT04322539)6: - Fruquintinib (Fruzaqla) improved the quality of life in patients with metastatic CRC when combined with best supportive care and significantly improved quality-adjusted time without symptoms of disease or toxicity compared with placebo and best supportive care. - The study showed positive effects on PFS, response rate, disease control, and duration of response with the fruquintinib combination. - The findings from this trial supported the FDA approval of fruquintinib for metastatic CRC in November 2023.7 References 1.        Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol. 2024(suppl 3):LBA588. doi:10.1200/JCO.2024.42.3_suppl.LBA588 2.        Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024;42(suppl 3):LBA432. doi.10.1200/JCO.2024.42.3_suppl.LBA432 3.        Andre T, Elez E, Van Cutsem E, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. J Clin Oncol. 2024;42(suppl_3):LBA768. doi.10.1200/JCO.2024.42.3_suppl.LBA768 4.        Kasi P, Aushev V, Ensor J, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study. J Clin Oncol. 2024;42 (suppl _3):9. doi:10.1200/JCO.2024.42.3_suppl.9 5.        Yukami H, Nakamura Y, Mishima S, et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN. J Clin Oncol. 2024;42(suppl_3):6. doi:10.1200/JCO.2024.42.3_suppl.6 6.        Stintzing S, Tabernero J, Satoh T, et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): results from the FRESCO-2 trial. J Clin Oncol. 2024;42(suppl 3):116. doi:10.1200/JCO.2024.42.3_suppl.116 7.        FDA approves fruquintinib in refractory metastatic colorectal cancer. FDA. News release. November 8, 2023. Accessed February 7, 2024. https://shorturl.at/isJW2

TOMB RAIDER I II III REMASTERED, avis par Yohann LemoreÀ savoir ► Sortie : 14/02/2024► Plateforme : PS4/PS5, One, Series X|S, PC, Nintendo Switch► Développeur : Aspyr ► Éditeur : Aspyr Media► Genre : AventureTomb Raider Soundtrack by Nathan McCree► https://www.youtube.com/watch?v=o8o_rmzGzP8&list=PLBBEB7990EE04D7BD

From music becoming illegal to sexual expression becoming illegal, Joe has quite the dystopian adventure. After plooking Sy Borg too hard, he ends up in jail and is forced to create music in his own mind to save himself from becoming a drone for this new "orderly" society. "The White Zone is for loading and unloading only. If you have load or unload, go to the White Zone. You'll love it." --The Central Scrutinizer Links: Everything you need to know about Joe's Garage: https://www.donlope.net/fz/notes/Joe%27s_Garage.html#Dong OUR DISCORD: https://discord.gg/2stA2P7pTC Flyover State Hotline - 1 608 HIT-NERD (608-448-6373) https://www.youtube.com/flyoverstatepark EVERYTHING ELSE: https://linktr.ee/FlyoverStatePark --- Support this podcast: https://podcasters.spotify.com/pod/show/albumconcepthour/support

Recorded by Brad Walrond for Poem-a-Day, a series produced by the Academy of American Poets. Published on February 2, 2024. www.poets.org

In episode #78 of

Next up on the ESMO 2023 rollercoaster is an episode that is likely to be the shortest in our series: upper gastrointestinal and hepatobiliary oncology. As always, this remains a very challenging subarea of medical oncology, both in the clinical and trial spheres. However, our esteemed colleagues at ESMO remain undaunted by this challenge, and thus several studies of interest bear discussing. Will any of these studies lead to massive upheavals for clinicians and patients alike? For that answer, you'll have to listen on.Links to studies discussed in this episodes (subscription may be required):Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/638034GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639003Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/637982For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Irgendwas mit Examen Folge 12: Taucht ein in die komplexe Welt der vorvertraglichen Haftung in dieser brandneuen Episode. Wie funktioniert die culpa in contrahendo (c.i.c.) und wie wird sie in der Klausur geprüft? Wir besprechen die berühmten Linoleum- und Salatblatt-Entscheidungen, um die Konzepte und Anwendungen der vorvertraglichen Haftung herzuleiten. Wie wird die Haftung bei einem Vertrag mit Schutzwirkung zugunsten Dritter gehandhabt und welche Rolle spielen die §§ 278, 311 II, III, 328, 831 BGB in diesem Kontext? Gemeinsam mit Prof. Dauner-Lieb entschlüsseln wir die komplizierten Haftungsmechanismen, zeigen auf, wie sie sich auf verschiedene Vertragsarten auswirken und geben Euch ein tieferes Verständnis über die entsprechenden gesetzlichen Regelungen. Wie immer wird Systemverständnis großgeschrieben und ihr erhaltet nach dem Podcast ein klares und präzises Verständnis der Thematik. Packt Eure Gesetzesbücher aus, macht es Euch gemütlich und bereitet Euch auf eine intensive Lernsession vor. Viel Spaß beim Zuhören!

3. The Practice of Psychotherapy III. The Question of Payment The holy relationship of the Psychotherapist and the Patient is not entered into for the money. Yet, an exchange may take place. The Therapist gives what he may see is needed, in terms of Forgiveness in himself and his patient, to take them both to a more sane place. The patient may supply the money the Therapist needs in order to do his work of this holy exchange. But all value is in the Holy Relationship in which the Therapist and Patient are seen as equals in the eyes of God, and all "thoughts that hurt" are forgiven in both, restoring both to JOY, and having a full healing of all pain and suffering.

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Join Ben and Collin as they break down all of the Christopher Reeve Superman films. And yes, even the fourth one.

Цикл передач об истории Средних веков. После падения дома Комнинов к власти в Византии пришел Исаак II Ангел. В это время против империи поднимаются Болгария и Сербия, они добиваются независимости. Несмотря на некоторые успехии Исаака II на поле боя, его свергает собственный брат Алексей III. Сын Исаака, будущий Алексей IV, бежит к крестоносцам, начавшим Четвертый Крестовый поход, и в 1203 году они помогают вертуть на трон Византии его и его отца. Однако в начале 1204 года вспыхивает восстание, к власти приходит Алексей V, он убирает Алексея IV и крестоносцы, в качестве мести за своего протеже, берут Константинополь и учреждают Латинскую империю. В разных частях бывшей Византии возникают также и греческие государственные образования. Одно из них в Эпире основывает Михаил Комнин Дука из рода Ангелов, кузен Исаака II и Алексея III. В 20-х годах XIII века его брат Феодор Комнин Дука берет под контроль Фессалию и Македонию и становится императором в Тессалониках. Но в 1230 году его разгромил болгарский царь, а в 1246 году Тессалоники перешли под власть Никейской империи. Эпирский деспотат остался независимым под властью Михаила II, но большой роли уже не играл.Присоединяйтесь к моему сообществу на Patreon: https://www.patreon.com/val_khokhlov Hosted on Acast. See acast.com/privacy for more information.

Commentary by Dr. Valentin Fuster

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

The Crew Meets The Godslayer. As they reunite after the initial breach, the crew is shocked to see the altercation between Xalduin and Oliver. After a brief discussion with Oliver, the crew takes a moment to communicate and reassign targets to the generals after seeing the initial fallout. This will get worse.Support the show

"Obi-Wan, promise... Promise me you will train the boy... He is the chosen one. He will bring balance. Train him." Rot Your Brain Media's (@rot_yourbrain) hosts Robbie, Max and special guest Joey rewatch director George Lucas' blockbuster Star Wars prequels 'The Phantom Menace,' 'Attack of the Clones' and 'Revenge of the Sith.'In Part 2, the guys break down Episode III - Revenge of the Sith, discuss their views on a few key characters and put this trilogy up against the original.Support Rot Your Brain Media by visiting patreon.com/RotYourBrainMediaSubscribe to the "Still Holds Up?" podcast feed at https://www.rotyourbrainmedia.com/stillholdsupSubscribe to Rot Your Brain Media feed at rotyourbrainmedia.comSend feedback to info@RotYourBrainMedia.comMusic by: Jason ZaffaryAdditional Bed: Kyle Tormey

"Obi-Wan, promise... Promise me you will train the boy... He is the chosen one. He will bring balance. Train him." Rot Your Brain Media's (@rot_yourbrain) hosts Robbie, Max and special guest Joey rewatch director George Lucas' blockbuster Star Wars prequels 'The Phantom Menace,' 'Attack of the Clones' and 'Revenge of the Sith.'In Part 1, the guys break down Episode I - The Phantom Menace, Episode II - Attack of the Clones, and discuss the "Duel of The Fates".Support Rot Your Brain Media by visiting patreon.com/RotYourBrainMediaSubscribe to the "Still Holds Up?" podcast feed at https://www.rotyourbrainmedia.com/stillholdsupSubscribe to Rot Your Brain Media feed at rotyourbrainmedia.comSend feedback to info@RotYourBrainMedia.comMusic by: Jason ZaffaryAdditional Bed: Kyle Tormey

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??

How do you build a massive mountain lobster? How long did we know that some folks were pixelated? And what hot dogs are the best hot dogs? All that and more on the Afterparty!   Here's the Shadow of the Colossus D&D zine, a completo, Crif Dogs, and a Seattle dog.    Sponsors - Hero Forge, where you can now get Color Standees! Visit heroforge.com to start designing your custom miniature today. - Squarespace. Go to squarespace.com/jointheparty for a free trial, and when you're ready to launch, use offer code JOINTHEPARTY to save 10% off your first purchase of a website or domain.  - BetterHelp, a secure online therapy service. Get 10% off your first month at betterhelp.com/jointheparty   Find Us Online - website: jointhepartypod.com - patreon: patreon.com/jointhepartypod - twitter: twitter.com/jointhepartypod - facebook: facebook.com/jointhepartypod - instagram: instagram.com/jointhepartypod - tumblr: jointhepartypod.tumblr.com - merch & music: jointhepartypod.com/merch   Cast & Crew - Dungeon Master, Co-Producer: Eric Silver - Co-Host (Milo Lane), Co-Producer, Editor, Sound Designer, Composer: Brandon Grugle - Co-Host (Aggie O'Hare), Co-Producer: Amanda McLoughlin - Co-Host (Val Vesuvio), Co-Producer, Editor: Julia Schifini - Multitude: multitude.productions   About Us Join the Party is a D&D actual play podcast with tangible worlds, genre-pushing storytelling, and collaborators who make each other laugh each week. We welcome everyone to the table, from longtime players to folks who've never touched a roleplaying game before. Begin with Campaign 2 (The Join Campaign) for a modern, sci-fi superhero game, or marathon all of Campaign 1 (The Party Campaign) for a high fantasy story. And once a month we release the Afterparty, where we answer your questions about the show and how we play the game. New episodes every Tuesday.